Transition of young adults with endocrine and metabolic diseases: the 'TRANSEND' cohort.

care pathway case management cohort endocrinology rare diseases transition to adult care

Journal

Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 23 10 2020
accepted: 25 11 2020
pubmed: 3 12 2020
medline: 3 12 2020
entrez: 2 12 2020
Statut: ppublish

Résumé

The transition from paediatric to adult medicine involves risks of poor patient outcomes and of significant losses of patients to follow up. The research aimed to analyse the implementation in an initial cohort of patients of a new programme of transition to adult care based on a case management approach. A longitudinal study of the case management approach to transition, initiated in a university hospital in France in September 2016. Patients with the endocrine or metabolic disease diagnosed during childhood and transferred to adult care were included. The transition programme includes three steps based on case management: liaising with paediatric services, personalising care pathways, and liaising with structures outside the hospital (general practitioners, agencies in the educational and social sector). The cohort included 500 patients, with malignant brain tumour (n = 56 (11%)), obesity (n = 55 (11%)), type 1 diabetes (n = 54 (11%)), or other disease (n = 335 (67%)). Their median age at transfer was 19, and the sex ratio was 0.5. At median 21 months of follow-up, 439 (88%) had a regular follow-up in or outside the hospital, 47 (9%) had irregular follow-up (absence at the last appointment or no appointment scheduled within the time recommended), 4 had stopped care on doctor's advice, 4 had died, 3 had moved, and 3 had refused care. The programme involved 9615 case management actions; 7% of patients required more than 50 actions. Patients requiring most support were usually those affected by a rare genetic form of obesity. Case managers successfully addressed the complex needs of patients. Over time, the cohort will provide unprecedented long-term outcome results for patients with various conditions who experienced this form of transition.

Identifiants

pubmed: 33263561
doi: 10.1530/EC-20-0520
pii: EC-20-0520
pmc: PMC7923139
doi:
pii:

Types de publication

Journal Article

Langues

eng

Pagination

21-28

Références

J Adolesc Health. 2015 Jun;56(6):612-8
pubmed: 26003575
Diabet Med. 2015 Apr;32(4):440-58
pubmed: 25407592
Arch Dis Child. 2015 Jun;100(6):559-64
pubmed: 25688098
Endocr Connect. 2017 Jul 18;6(7):422-429
pubmed: 28720594
Horm Res Paediatr. 2012;78(4):247-55
pubmed: 23128858
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Pediatrics. 2002 Dec;110(6 Pt 2):1304-6
pubmed: 12456949
Pediatrics. 2016 Jul;138(1):
pubmed: 27354452
Best Pract Res Clin Endocrinol Metab. 2015 Jun;29(3):497-504
pubmed: 26051305
Ann Endocrinol (Paris). 2009 Mar;70(1):14-24
pubmed: 19178907
Am J Health Syst Pharm. 2019 Sep 16;76(19):1544-1554
pubmed: 31532501
Curr Diab Rep. 2013 Dec;13(6):900-8
pubmed: 24014075
Diabetes Care. 2011 Nov;34(11):2477-85
pubmed: 22025785
Lancet. 2009 Jun 13;373(9680):2027-33
pubmed: 19481249
BMJ. 2016 May 11;353:i2225
pubmed: 27170336
Pediatrics. 2013 Apr;131(4):e1062-70
pubmed: 23530167
Child Care Health Dev. 2011 Nov;37(6):821-32
pubmed: 22007982
BMJ Open. 2017 Jan 27;7(1):e012338
pubmed: 28131998
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
Paediatr Child Health. 2007 Nov;12(9):785-93
pubmed: 19030468
Clin Endocrinol (Oxf). 2013 Jan;78(1):23-8
pubmed: 23009615
Clin Endocrinol (Oxf). 2009 Sep;71(3):346-50
pubmed: 19178523
Eur J Pediatr. 2020 Jan;179(1):61-71
pubmed: 31515671
J Pediatr Endocrinol Metab. 2019 May 27;32(5):505-511
pubmed: 31028713
J Pediatr. 2017 Sep;188:263-269.e15
pubmed: 28668449

Auteurs

Enora Le Roux (E)

Université de Paris, ECEVE UMR 1123, Inserm, Paris, France.
AP-HP.Nord-Université de Paris, Hôpital Universitaire Robert Debré, Unité d'Épidémiologie Clinique, Inserm, Paris, France.

Florence Menesguen (F)

AP-HP. Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière-Charles Foix, Service d'Endocrinologie et Médecine de la Reproduction, Centre de Maladies Endocriniennes Rares de la Croissance et du Développement, Centre de Pathologies Gynécologiques Rares, Paris, France.

Isabelle Tejedor (I)

AP-HP. Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière-Charles Foix, Service d'Endocrinologie et Médecine de la Reproduction, Centre de Maladies Endocriniennes Rares de la Croissance et du Développement, Centre de Pathologies Gynécologiques Rares, Paris, France.

Marc Popelier (M)

AP-HP. Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière-Charles Foix, Service de Diabétologie, Paris, France.

Marine Halbron (M)

AP-HP. Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière-Charles Foix, Service de Diabétologie, Paris, France.

Pauline Faucher (P)

AP-HP. Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière-Charles Foix, Service de Nutrition, Centre du Syndrome de Prader-Willi et Autres Obésités Rares, Paris, France.

Sabine Malivoir (S)

AP-HP. Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière-Charles Foix, Service d'Endocrinologie et Médecine de la Reproduction, Centre de Maladies Endocriniennes Rares de la Croissance et du Développement, Centre de Pathologies Gynécologiques Rares, Paris, France.

Graziella Pinto (G)

AP-HP.Université de Paris Centre, Hôpital Universitaire Necker Enfants Malades, Département d'Endocrinologie, Diabétologie et Gynécologie Pédiatrique, Paris, France; Centre de Maladies Endocriniennes Rares de la Croissance et du Développement, Centre de Pathologies Gynécologiques Rares, Paris, France.

Juliane Léger (J)

AP-HP.Nord-Université de Paris, Hôpital Universitaire Robert Debré, Service d'Endocrinologie Diabétologie Pédiatrique, Centre de Référence des Maladies Endocriniennes de la Croissance et du Développement, Paris, France.

Stephane Hatem (S)

Institute of Cardiology and Nutrition, Paris, France.

Michel Polak (M)

AP-HP.Université de Paris Centre, Hôpital Universitaire Necker Enfants Malades, Département d'Endocrinologie, Diabétologie et Gynécologie Pédiatrique, Paris, France; Centre de Maladies Endocriniennes Rares de la Croissance et du Développement, Centre de Pathologies Gynécologiques Rares, Paris, France.

Christine Poitou (C)

AP-HP. Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière-Charles Foix, Service de Nutrition, Centre du Syndrome de Prader-Willi et Autres Obésités Rares, Paris, France.

Philippe Touraine (P)

AP-HP. Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière-Charles Foix, Service d'Endocrinologie et Médecine de la Reproduction, Centre de Maladies Endocriniennes Rares de la Croissance et du Développement, Centre de Pathologies Gynécologiques Rares, Paris, France.

Classifications MeSH